Search Results


FDA approved 24 drugs in 2022 based on a SINGLE study

https://www.naturalnews.com/2023-08-17-fda-approved-24-drugs-in-2022-based-on-a-single-study.html

August 17, 2023 - aducanumab – was approved to treat Alzheimer’s. According to David Gortler, a pharmacologist and FDA reform advocate at the Ethics and Public Policy Center, the FDA expedited the drug’s approval “based on zero positive studies.”

The Act not only provided $500 million in taxpayer dollars over nine years to facilitate the corruption at the FDA, but it also provided an additional $6.3 billion to the National Institutes of Health to expedite research at American universities....

FDA approves controversial drug for use against Alzheimer’s disease, despite evidence showing it doesn’t work

https://www.naturalnews.com/2021-07-02-fda-approves-controversial-alzheimers-drug.html

July 02, 2021 -

The drug, known as aducanumab, is the first Alzheimer's treatment approved by the FDA in almost 20 years. It will be marketed as Aduhelm. Biogen is also charging $56,000 per year for aducanumab. It is meant to be given as an infusion every four weeks.

The FDA approved the drug based on the results of studies that showed it seemed "reasonably likely" to benefit Alzheimer's patients. It is also the only therapy that regulators have said can likely treat ...

New FDA-approved “miracle” drugs ACCELERATE formation of arthritis, Alzheimer’s

https://www.naturalnews.com/2023-01-17-new-fda-miracle-drug-accelerates-arthritis-alzheimers.html

January 17, 2023 - aducanumab), which recently gained approval from the U.S. Food and Drug Administration (FDA).

Aduhelm received "accelerated approval" from the FDA, which in the context of a major drug rollout is an instant red flag. This almost always means that corners were cut, or safety and efficacy standards reduced, to demonstrate its "safety and effectiveness."

"Aduhelm received 'accelerated approval' from the FDA in June despite the fact that an independent panel ...

ICER: FDA failed to protect patients from unproven Alzheimer’s treatment with known harms

https://www.naturalnews.com/2021-06-13-fda-failed-to-protect-alzheimers-patients-from-harm.html

June 13, 2021 - aducanumab that might have helped to resolve disputes about efficacy quickly and cleanly," Howard said. "Now, we'll wait a decade before it becomes obvious to everyone that there are no benefits – only high healthcare costs – associated with the treatment."Biogen slammed over decision to price Aduhelm at $56,000 per year

Meanwhile, Biogen has been taking flak over its decision to price Aduhelm at $56,000 per year. ICER said a fair price would be in the $2,500 to $8,300 ...


Free Email Alerts
Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.
App Store
Android App
eTrust Pro Certified

This site is part of the Natural News Network © All Rights Reserved. Privacy | Terms All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing International, LTD. is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. Truth Publishing assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published here. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.

This site uses cookies
Natural News uses cookies to improve your experience on our site. By using this site, you agree to our privacy policy.
Learn More
Close
Get 100% real, uncensored news delivered straight to your inbox
You can unsubscribe at any time. Your email privacy is completely protected.